logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
6/2/2019 9:14:43 AM Aimmune Therapeutics Presents Topline Results From Pivotal European Phase 3 ARTEMIS Clinical Trial
3/25/2019 8:13:44 AM Aimmune Therapeutics Says European Phase 3 Trial Of AR101 Meets Primary Endpoint
3/19/2019 7:59:28 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY20 Rev. Estimate To 52.3 M From 78.6 M
3/19/2019 7:45:52 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q4 20 Rev. Estimate To 31.4 M From 42.8 M
3/19/2019 7:45:38 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q3 20 Rev. Estimate To 11.0 M From 19.6 M
3/19/2019 7:45:26 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q2 20 Rev. Estimate To 6.8 M From 11.7 M
3/19/2019 7:44:44 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q1 20 Rev. Estimate To 3.2 M From 4.5 M
3/19/2019 7:44:18 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY20 Estimate To -3.07 From -2.71
3/19/2019 7:44:05 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q4 20 Estimate To -0.53 From -0.37
3/19/2019 7:43:50 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q3 20 Estimate To -0.80 From -0.68
3/19/2019 7:43:35 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q2 20 Estimate To -0.85 From -0.78
3/19/2019 7:43:19 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q1 20 Estimate To -0.89 From -0.87
3/19/2019 7:43:03 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -3.66 From -3.63
3/19/2019 7:42:49 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q4 19 Estimate To -0.95 From -0.92
3/19/2019 7:42:02 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $76 Down From $80 Price Target
3/18/2019 8:04:35 AM FDA Accepts BLA Filing Of Aimmune Therapeutics’ AR101 For Peanut Allergy
2/5/2019 7:58:06 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $80 Price Target